Acute Lymphoblastic LeukemiaChronic Lymphocytic LeukemiaClinical Consult: Assessing the Impact of Tailor XColorectal CancerGastrointestinal CancerGastrointestinal Cancer QuizHead & Neck CancerHER2-Positive Breast CancerImmune Thrombocytopenic PurpuraLymphomaRenal Cell CarcinomaTelehealth

Brain CancerBreast CancerGastrointestinal CancerGenitourinary CancerGynecologic CancerHematologyLeukemiaLung CancerLymphomaPediatric CancersSkin Cancer

News

All NewsNP/PAPractice ManagementTechnology

Media

Expert InterviewsMedical World NewsTumor Board Series

Conferences

Publications

Resources

CMEImage IQPodcastsPollsQuizzesSlideshows

eNewsletterPrint Subscription

Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information

Spotlight

Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Clinical Consult: Assessing the Impact of Tailor X
Colorectal Cancer
Gastrointestinal Cancer
Gastrointestinal Cancer Quiz
Head & Neck Cancer
HER2-Positive Breast Cancer
Immune Thrombocytopenic Purpura
Lymphoma
Renal Cell Carcinoma
Telehealth

ClinicalSee All >

Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer

Eisai Acquires Four Oncology- Related Products From Ligand

December 1, 2006

Eisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.

TEANECK, New JerseyEisai Inc., the US subsidiary of Tokyo-based Eisai Co. Ltd., has completed acquisition of four oncology-related products from Ligand Pharmaceuticals: Ontak (denileukin diftitox), Targretin (bexarotene) capsules, Targretin (bexarotene) gel 1%, and Panretin (alitretinoin gel 0.1%. In other news, the company said it has begun work on a new oncology facility in Research Triangle Park, North Carolina.